share_log

PHCHD、サイフューズと3D細胞製品の商業化で新たな生産技術を開発

PHCHD has developed a new production technology for the commercialization of 3D cell products in collaboration with Cyfuse.

Kabushiki Shimbun ·  Mar 19 05:27

On the 19th, PHC Holdings <6523.T> announced that its subsidiary PHC has developed a new production technology in collaboration with Cyfuse <4892.T> based on a business partnership and joint research aimed at commercialization in the field of regenerative and cell medicine.

According to the company, this technology enables real-time monitoring of cell quality for "living cells" and "three-dimensional cells," which have been technically challenging until now, leading to improvements in the quality of cell products and stable manufacturing. Specifically, by combining the three-dimensional cell structures manufactured using Cyfuse's proprietary foundational technology "Bio 3D Printing" with the In-Line monitoring technology installed in the automatic culture device "LiCellGrow" currently under development by PHC, improvements and stabilization of cell product quality have been achieved.

As of 2:21 PM, the stock price is 1,075 yen, up 4 yen from the previous day.

Provided by Wealth Advisor Company.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 360

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.